Skip to main content
Vedana Therapeutics logo

Vedana Therapeutics

Seattle, Washington, United StatesSee on the mapFounded 2024

  • Series A

Vedana Therapeutics is a biotechnology company advancing therapeutic antibody programs. Its team supports the development of mono- and multispecific antibodies from discovery and protein engineering through preclinical development and preparation for first-in-human studies.

Raised
$46M
Jun 2026
Series A
Investors
4
Founded
2024
Employees
11–50

reccy insights

Recent highlights

Vedana Therapeutics’ clearest disclosed milestone is its $46 million Series A, announced on Jun 17, 2026. The round lists Canaan Partners, Westlake Village BioPartners, Alexandria Venture Investments, and Dawn Biopharma among its investors. The financing gives the Seattle-based company capital to advance its therapeutic antibody work, although specific funded programs, spending plans, and development timelines have not been disclosed. Founded in 2024, Vedana is developing preventive migraine therapies and describes capabilities spanning antibody discovery, protein engineering, pharmacology, bioanalysis, and preclinical development. Its stated scope includes monoclonal and multispecific antibody programs, with work intended to progress from discovery toward first-in-human preparation. The available details therefore point to a financing and platform-building phase rather than a publicly documented clinical or commercial inflection point.

Written by reccy's AI from company sites, press and funding records · updated Nov 2026

What makes Vedana Therapeutics distinct

  1. 01Combines expertise in antibody discovery, protein sciences, pharmacology, bioanalysis, and program management.
  2. 02Team experience spans biologics development from discovery through preclinical work, IND-enabling activities, and clinical development.
  3. 03Works across both monoclonal and multispecific antibody programs.
  4. 04Leadership and scientific experience includes biotechnology companies such as Alder Biopharmaceuticals, Amgen, Aptevo Therapeutics, and Regeneron.

Technology & products

  • Therapeutic antibody discovery and development
  • Monoclonal and multispecific antibody programs
  • Protein engineering and antibody optimization
  • Preclinical pharmacology and bioanalytical assay development

Recent updates1

  • Jun 17, 2026Product launch

    Vedana Therapeutics Launches With $46 Million Series A Financing to Advance Next-Generation Migraine Therapies

    businesswire.com

Funding

$46M disclosed
4 investors

Investors4

Also backed by
  • Canaan Partners
  • Westlake Village BioPartners
  • Dawn Biopharma

About Vedana Therapeutics

Leadership
Anurag AgarwalLeon Martinez
Focus areas
Biotechnology, therapeutics, antibodies, biologics, drug discovery, protein engineering, preclinical development, immuno oncology
Headquarters
Seattle, Washington, United States
Founded
2024
Employees
11–50
Status
Active · private